HAYWARD, Calif., June 30, 2026
RefleXion Medical has announced the submission of a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) seeking clearance for Anchor Point™ Tracking, an advanced tumor-tracking technology developed for its next-generation RefleXion® X2 platform. The submission represents a significant advancement in SCINTIX® autonomous radiotherapy, further enhancing biologically guided cancer treatment through improved real-time tumor tracking. Powered by the X2 platform’s 20-fold increase in positron emission tomography (PET) sensitivity, Anchor Point Tracking is designed to deliver greater treatment precision by continuously identifying stable biologic markers within tumors during radiation delivery. If cleared, the technology could significantly expand the clinical capabilities of SCINTIX therapy, enabling treatment across a broader range of tumor sizes, anatomical locations, and motion characteristics while improving radiation accuracy and patient outcomes. The submission reinforces RefleXion’s commitment to advancing external beam theranostic oncology through intelligent imaging and autonomous treatment technologies.
Next-Generation Tumor Tracking Enhances SCINTIX Therapy
The newly submitted Anchor Point™ Tracking technology is built upon the enhanced capabilities of the RefleXion X2 platform, which achieves a 20-fold improvement in PET sensitivity by incorporating four times more onboard PET detectors than previous-generation systems. The increased biologic imaging capability enables the development of sophisticated autonomous treatment algorithms capable of continuously identifying a stable biologic “anchor point” within PET data to guide radiation delivery with greater precision.
Unlike conventional image-guided radiotherapy that primarily relies on anatomical imaging, SCINTIX® therapy uses a single radiotracer injection to transform cancer cells into real-time biologic beacons, allowing radiation beams to automatically follow tumors throughout treatment. By combining enhanced PET imaging with advanced tracking algorithms, Anchor Point Tracking is expected to improve treatment accuracy, optimize dose delivery, and strengthen motion management for tumors affected by breathing or other physiological movement.
Clinical Validation Supports Improved Treatment Precision
Advertisement
RefleXion’s FDA 510(k) submission is supported by extensive system validation studies and phantom testing, demonstrating the performance and reliability of the Anchor Point Tracking technology. In parallel, leading academic investigators evaluated the X2 platform and reported improvements in several critical radiotherapy performance measures, including tumor target tracking, radiation dose conformity, motion management, and organ-at-risk sparing. These findings demonstrate the technology’s potential to deliver more precise radiation while minimizing unnecessary exposure to surrounding healthy tissues.
The supporting research is scheduled for presentation during the 2026 American Association of Physicists in Medicine (AAPM) Annual Meeting, highlighting growing scientific interest in biologically guided autonomous radiotherapy. If regulatory clearance is granted, Anchor Point Tracking could significantly expand the range of clinical scenarios suitable for SCINTIX therapy, particularly in patients with complex tumor motion or challenging anatomical locations.
RefleXion Expands the Future of Autonomous Radiotherapy
RefleXion Medical continues to position itself at the forefront of theranostic oncology through the integration of advanced imaging, artificial intelligence, and adaptive radiation delivery. The company’s SCINTIX® autonomous radiotherapy platform has already received FDA clearance for FDG-guided treatment of primary and metastatic lung and bone tumors, while the RefleXion X2 platform is also cleared for conventional image-guided radiotherapy across a broad range of solid tumors.
The addition of Anchor Point™ Tracking represents the next stage in the company’s vision of highly personalized, biologically guided cancer treatment capable of continuously adapting therapy based on each patient’s unique tumor biology. As precision oncology continues evolving toward increasingly intelligent treatment platforms, RefleXion’s latest FDA submission highlights the growing role of advanced PET-guided radiotherapy in improving cancer treatment accuracy, expanding therapeutic flexibility, and enhancing long-term patient care.
Source: RefleXion Medical press release
